Search research articles
Contact Us
Filters
Showing results (21-30 of 123) with videos related to
Page
of 13
Sort By:
Biomaterials
|
May 10, 2015
Synthesis of a novel, sequentially active-targeted drug delivery nanoplatform for breast cancer therapy
Arpan Satsangi, Sudipa S Roy, Rajiv K Satsangi, et al.
Cancer Chemotherapy and Pharmacology
|
June 4, 2010
A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer
Anthony W Tolcher, Leonard J Appleman, Geoffrey I Shapiro, et al.
Cancer Chemotherapy and Pharmacology
|
November 27, 2012
A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors
Raoul Tibes, Gil Fine, Gavin Choy, et al.
Oncoimmunology
|
March 14, 2013
Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors
Robert H Vonderheide, Jennifer M Burg, Rosemarie Mick, et al.
Investigational New Drugs
|
March 20, 2019
A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody-drug conjugate, in patients with breast cancer and other advanced solid tumors
Lee S Rosen, Robert Wesolowski, Raffaele Baffa, et al.
Investigational New Drugs
|
August 5, 2004
A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies
Garry H Schwartz, Christopher B Jones, Mitchell Garrison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 3, 2008
Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study
Alejandro D Ricart, Anthony W Tolcher, Glenn Liu, et al.
American Journal of Clinical Oncology
|
February 6, 2009
A phase I dose-escalation study of SR271425, an intravenously dosed thioxanthone analog, administered weekly in patients with refractory solid tumors
A Craig Lockhart, Emiliano Calvo, Anthony W Tolcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 22, 2010
Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors
Quincy Chu, Alain Mita, Bahram Forouzesh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 28, 2025
A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors
Lillian L Siu, Timothy A Yap, Sofia Genta, et al.
Page
of 13
Search research articles
Search
Showing results (21-30 of 123) with videos related to
Sort By:
Page
of 13
Biomaterials
|
May 10, 2015
Synthesis of a novel, sequentially active-targeted drug delivery nanoplatform for breast cancer therapy
Arpan Satsangi, Sudipa S Roy, Rajiv K Satsangi, et al.
Cancer Chemotherapy and Pharmacology
|
June 4, 2010
A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer
Anthony W Tolcher, Leonard J Appleman, Geoffrey I Shapiro, et al.
Cancer Chemotherapy and Pharmacology
|
November 27, 2012
A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors
Raoul Tibes, Gil Fine, Gavin Choy, et al.
Oncoimmunology
|
March 14, 2013
Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors
Robert H Vonderheide, Jennifer M Burg, Rosemarie Mick, et al.
Investigational New Drugs
|
March 20, 2019
A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody-drug conjugate, in patients with breast cancer and other advanced solid tumors
Lee S Rosen, Robert Wesolowski, Raffaele Baffa, et al.
Investigational New Drugs
|
August 5, 2004
A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies
Garry H Schwartz, Christopher B Jones, Mitchell Garrison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 3, 2008
Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study
Alejandro D Ricart, Anthony W Tolcher, Glenn Liu, et al.
American Journal of Clinical Oncology
|
February 6, 2009
A phase I dose-escalation study of SR271425, an intravenously dosed thioxanthone analog, administered weekly in patients with refractory solid tumors
A Craig Lockhart, Emiliano Calvo, Anthony W Tolcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 22, 2010
Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors
Quincy Chu, Alain Mita, Bahram Forouzesh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 28, 2025
A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors
Lillian L Siu, Timothy A Yap, Sofia Genta, et al.
Page
of 13